- Results from a multicenter, retrospective study suggest that first-line (1L) anti-programmed death 1 (PD-1) therapy is associated with longer OS compared with MAPK inhibitors in patients with BRAF-mutated advanced melanoma.
Why this matters
- This multicenter analysis fills the gap left by lack of head-to-head trials.
- Patients treated with anti-PD-1 monotherapy had longer median OS compared with patients treated with MAPK inhibitors (29.1 vs 12.4 months; P<.001 style="list-style-type:circle;">
- 26.6 vs 18.6 months in patients with normal lactase dehydrogenase (LDH) levels (P<.001>
- 18.2 vs 9.2 months in patients with elevated LDH levels (P=.019).
- 301 patients with unresectable/metastatic, BRAF-mutant melanoma, 106 treated with anti-PD-1 monotherapy (61.9% pembrolizumab, 38.1% nivolumab) and 195 with combined MAPK inhibitors (80.5% dabrafenib plus trametinib, 19.5% vemurafenib plus cobimetinib), were analyzed for survival.
- Funding: None.
- Retrospective study.